May Hill Capital LLC Raises Stock Holdings in Novo Nordisk A/S $NVO

May Hill Capital LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 188.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,212 shares of the company’s stock after buying an additional 15,808 shares during the quarter. May Hill Capital LLC’s holdings in Novo Nordisk A/S were worth $1,232,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Burford Brothers Inc. boosted its stake in Novo Nordisk A/S by 7.1% in the fourth quarter. Burford Brothers Inc. now owns 10,798 shares of the company’s stock worth $549,000 after buying an additional 717 shares in the last quarter. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 186.8% in the fourth quarter. Center for Financial Planning Inc. now owns 2,134 shares of the company’s stock worth $109,000 after buying an additional 1,390 shares in the last quarter. Stephens Inc. AR boosted its stake in Novo Nordisk A/S by 19.2% in the fourth quarter. Stephens Inc. AR now owns 29,946 shares of the company’s stock worth $1,524,000 after buying an additional 4,818 shares in the last quarter. Novare Capital Management LLC boosted its stake in Novo Nordisk A/S by 38.0% in the fourth quarter. Novare Capital Management LLC now owns 5,585 shares of the company’s stock worth $284,000 after buying an additional 1,539 shares in the last quarter. Finally, Phoenix Financial Ltd. boosted its stake in Novo Nordisk A/S by 11.7% in the fourth quarter. Phoenix Financial Ltd. now owns 122,154 shares of the company’s stock worth $6,213,000 after buying an additional 12,828 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
• Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
• Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
• Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
• Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
• Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
• Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
• Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price for the company. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $44.71 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a market capitalization of $199.63 billion, a P/E ratio of 10.50, a PEG ratio of 3.98 and a beta of 0.77. The stock has a 50 day moving average price of $39.73 and a two-hundred day moving average price of $46.69. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion during the quarter. Analysts expect that Novo Nordisk A/S will post 3.47 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.